Hospital Provincial De Conxo

The ophthalmology unit at Hospital Provincial De Conxo conducts studies on a range of ocular conditions. Research includes neovascular age‑related macular degeneration and evaluates innovative anti‑VEGF and gene‑based therapies. Trials also address uveal melanoma with targeted treatment strategies. Post‑cataract surgery inflammation is examined through novel steroid nanoemulsion safety studies. Another focus is thyroid eye disease, testing biologic agents to reduce proptosis. The goal is to preserve vision and prevent eye loss in severe disease.

• Neovascular AMD – anti‑VEGF and gene‑based approaches
• Uveal melanoma – targeted therapy evaluation
• Post‑cataract surgery inflammation – steroid nanoemulsion safety
• Thyroid eye disease – biologic efficacy study
• Vision preservation in severe ocular disease

These investigations bring cutting‑edge treatments to patients in Santiago de Compostela. The program supports the hospital’s commitment to advancing ocular health across Europe.

The site’s immune‑focused research targets allergic airway and eye disorders. A key study evaluates allergic rhinoconjunctivitis using subcutaneous allergen extracts. Parallel work investigates a dust‑mite allergy vaccine for safety and efficacy. Patients with coexisting asthma are included to assess integrated treatment benefits. The overarching aim is to reduce symptom burden and improve quality of life for individuals with immune‑mediated conditions.

• Allergic rhinitis/rhinoconjunctivitis – subcutaneous allergen extracts
• Dust‑mite vaccine – efficacy and safety assessment
• Asthma comorbidity – integrated therapeutic strategies
• Ocular inflammation linked to immune dysfunction

Collaboration with national allergy specialists expands access to novel immunotherapies throughout Spain. The department leverages its ophthalmology expertise to study ocular inflammation linked to immune dysfunction.

Clinical investigations also address chronic inflammatory skin diseases. A pivotal trial tests a new agent for Hidradenitis Suppurativa to lower disease activity. Research explores skin‑related immune pathways that may influence ocular outcomes. The program aims to translate findings into better management options for patients with difficult‑to‑treat skin conditions.

• Hidradenitis Suppurativa – novel anti‑inflammatory drug trial
• Skin‑immune mechanisms – translational research
• Connective tissue involvement in ocular disease – exploratory studies

By integrating dermatology insights, Hospital Provincial De Conxo strengthens its multidisciplinary approach. The effort contributes to broader therapeutic advances across Europe.